Chemoradiotherapy using retrograde superselective intra-arterial infusion for advanced oral cancer

Mitsudo Kenji, Iwai Toshinori, Mitsunaga Sachiyo, Oguri Senri, Koizumi Toshiyuki, Kioi Mitomu, Hirota Makoto, Tamari Masayuki, Yamamoto Noriyuki, Ueda Minoru, Tohnai Iwai

doi:10.5981/jjhnc.37.386

Concurrent chemoradiotherapy using retrograde superselective intra-arterial infusion demonstrates good local control and overall survival rates due to the advantage of simultaneous infusion of anticancer agent with the synergistic effects of chemotherapy and radiotherapy. This study evaluated the therapeutic results, overall survival and local control rates in patients with advanced oral cancer treated with definitive concurrent chemoradiotherapy using retrograde superselective intra-arterial infusion.<br>A total of 688 patients with carcinoma of the head and neck were referred to our institution between January 2001 and December 2006. Among them, 175 patients with carcinoma of the oral cavity underwent definitive concurrent chemoradiotherapy using retrograde superselective intra-arterial infusion. Treatment consisted of superselective intra-arterial infusions (docetaxel, total 60 mg/m², cisplatin, total 125-150 mg/m²) and daily concurrent radiotherapy (total 50-60 Gy) for 5-6 weeks. Four weeks after the completion of all treatments, patients underwent biopsy of the primary lesion and radiological examinations. Complete response (CR) of the primary site was achieved in 160 (91.4%) of the 175 patients. Residual disease at the primary site was seen in 15 patients (8.6%), and 14 patients (8.0%) showed local recurrence during follow-up. Five-year survival and local control rates were 71.6% and 82.2%, respectively.

Chemoradiotherapy using retrograde superselective intra-arterial infusion for advanced oral cancer

Bibliographic Information

Abstract

Journal

Citations (3)*help

References(10)*help

Keywords

Details 詳細情報について

Export

Report a problem